Purple Biotech Ltd ADR (PPBT) Stock Price, Quote & News

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 933 3121

Fax: 972 3 509 7196

Website: purple-biotech.com

Address:

4 Oppenheimer Street, Science Park, Rehovot, Israel

65creedmore Mar. 16 at 3:21 AM

$PPBT lots of volume coming in

0 · Reply

Winorbust Mar. 14 at 5:02 AM

$PPBT it’s a shame what this stock ended up being. Potential was there, about 5 years ago, when the fraud was just starting to show itself

0 · Reply

robobull Mar. 14 at 3:58 AM

$PPBT wow! Surprised this scam still alive. Got to ask though, what happened to stocksavior? Noticed he gone.

1 · Reply

Covence Mar. 14 at 1:18 AM

$PPBT this clearly means BO, right? Brad?

0 · Reply

Stocktelligence Mar. 13 at 11:30 PM

$PPBT new ATL 3.70 3.5M MC now

0 · Reply

StocHolliday Mar. 13 at 9:27 PM

$PPBT

0 · Reply

Purplepayday Mar. 13 at 8:36 PM

$PPBT Don’t worry, it’s all good… But, very interesting reading 👇 https://fortune.com/2026/03/13/national-debt-100-trillion-kent-smetters-penn-wharton/

0 · Reply

bigstocks307 Mar. 13 at 6:46 PM

$PPBT Hey Gill, I and others have recently hit our 5 year mark investing in your company. How long until we see our 5 Year Participation Award Certificate in the mail? Asking for Dr. lASSiter.

0 · Reply

Smittysixty Mar. 13 at 6:14 PM

$PPBT The Signals Are Clear Retail should see this for what it is: ✔ A company doubling down on a validated platform ✔ Two development‑ready tri‑specific antibodies ✔ A clean balance sheet ✔ A long runway ✔ A CEO moving into deal‑making ✔ FDA approval ready assets positioned for partnering ✔ A setup for strategic activity This is not a company collapsing. This is a company positioning itself for value‑creating events.

0 · Reply

Smittysixty Mar. 13 at 6:13 PM

$PPBT The CEO Transition Is Strategic, Not a Firing Gil is stepping down for health reasons but staying on the Board and taking over corporate development — the role that handles partnerships and strategic deals. If he were the problem, he’d be gone. Instead, they put him in the most important seat for the next phase.

0 · Reply

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

Nov 14, 2025, 8:00 AM EST - 4 months ago

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 29, 2025, 7:33 AM EDT - 4 months ago

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Oct 20, 2025, 4:00 PM EDT - 5 months ago

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

Sep 5, 2025, 4:00 PM EDT - 6 months ago

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Aug 27, 2025, 7:00 AM EDT - 7 months ago

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 6, 2025, 7:00 AM EDT - 7 months ago

Purple Biotech Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:00 AM EDT - 8 months ago

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Jun 23, 2025, 7:00 AM EDT - 9 months ago

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

May 21, 2025, 7:10 AM EDT - 10 months ago

Purple Biotech Reports First Quarter 2025 Financial Results

May 12, 2025, 7:30 AM EDT - 10 months ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Apr 28, 2025, 8:28 AM EDT - 11 months ago

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Mar 10, 2025, 8:57 AM EDT - 1 year ago

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 18, 2025, 7:00 AM EST - 1 year ago

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Dec 5, 2024, 7:13 AM EST - 1 year ago

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 3, 2024, 8:23 AM EST - 1 year ago

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 2, 2024, 9:18 AM EST - 1 year ago

Why Is Purple Biotech Stock Trading Higher On Monday?

Nov 15, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 7:50 AM EST - 1 year ago

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Oct 25, 2024, 7:20 AM EDT - 1 year ago

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 8:12 AM EDT - 1 year ago

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Jul 25, 2024, 7:35 AM EDT - 1 year ago

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Jul 2, 2024, 4:00 PM EDT - 1 year ago

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Jul 1, 2024, 9:00 AM EDT - 1 year ago

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Jun 27, 2024, 7:45 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

May 21, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 2 years ago

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Mar 14, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Mar 5, 2024, 7:55 AM EST - 2 years ago

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 27, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Feb 13, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Feb 1, 2024, 7:30 AM EST - 2 years ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Dec 20, 2023, 8:05 AM EST - 2 years ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dec 14, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Nov 21, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 3:55 PM EDT - 2 years ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Purple Biotech Announces $5 Million Registered Direct Offering

Oct 6, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Oct 3, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Aug 22, 2023, 9:29 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results

Jul 11, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

May 16, 2023, 4:00 PM EDT - 3 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Apr 19, 2023, 8:15 AM EDT - 3 years ago

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Apr 18, 2023, 7:00 AM EDT - 3 years ago

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Mar 24, 2023, 7:00 AM EDT - 3 years ago

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

65creedmore Mar. 16 at 3:21 AM

$PPBT lots of volume coming in

0 · Reply

Winorbust Mar. 14 at 5:02 AM

$PPBT it’s a shame what this stock ended up being. Potential was there, about 5 years ago, when the fraud was just starting to show itself

0 · Reply

robobull Mar. 14 at 3:58 AM

$PPBT wow! Surprised this scam still alive. Got to ask though, what happened to stocksavior? Noticed he gone.

1 · Reply

Covence Mar. 14 at 1:18 AM

$PPBT this clearly means BO, right? Brad?

0 · Reply

Stocktelligence Mar. 13 at 11:30 PM

$PPBT new ATL 3.70 3.5M MC now

0 · Reply

StocHolliday Mar. 13 at 9:27 PM

$PPBT

0 · Reply

Purplepayday Mar. 13 at 8:36 PM

$PPBT Don’t worry, it’s all good… But, very interesting reading 👇 https://fortune.com/2026/03/13/national-debt-100-trillion-kent-smetters-penn-wharton/

0 · Reply

bigstocks307 Mar. 13 at 6:46 PM

$PPBT Hey Gill, I and others have recently hit our 5 year mark investing in your company. How long until we see our 5 Year Participation Award Certificate in the mail? Asking for Dr. lASSiter.

0 · Reply

Smittysixty Mar. 13 at 6:14 PM

0 · Reply

Smittysixty Mar. 13 at 6:13 PM

0 · Reply

Smittysixty Mar. 13 at 6:12 PM

$PPBT Cash Runway Into 2027 PB ended 2025 with $9.5M and expects to operate into 2027. That means: ✔ No emergency dilution ✔ No panic financing ✔ Time to negotiate partnerships from a position of strength This is the opposite of a distressed biotech.

0 · Reply

Smittysixty Mar. 13 at 5:39 PM

$PPBT CM‑24 and NT‑219 Are NOT Dead PB didn’t kill the older drugs. They simply aren’t funding them internally right now because they're essentially approval and partner given the FDA trial change. Under accounting rules, that forces an “impairment,” but it has nothing to do with the science. Both drugs are still alive — they just need a partner.

0 · Reply

Smittysixty Mar. 13 at 5:36 PM

$PPBT IM1305 Is Officially a Development Candidate IM1305 isn’t just “in discovery” anymore. It’s validated, named, and ready for development. PB now has two tri‑specific antibodies with real data behind them. That’s a platform — not a single‑asset biotech.

0 · Reply

Smittysixty Mar. 13 at 5:36 PM

$PPBT IM1240 Hit Major De‑Risking Milestones The filing confirms IM1240 has: ✔ Strong anti‑tumor activity ✔ 300x safer dosing vs older T‑cell engagers ✔ Minimal cytokine release (huge safety win) ✔ Longer half‑life ✔ Commercial‑grade manufacturing achieved This is exactly what big pharma looks for before Phase 1.

0 · Reply

Smittysixty Mar. 13 at 5:36 PM

$PPBT CAPTN‑3 Is Now the Core of the Company PB officially shifted its identity to a next‑gen immunotherapy platform company. IM1240 and IM1305 aren’t concepts — they’re validated, development‑ready assets. This is the kind of pivot companies make when they’ve found the technology that will define their future.

0 · Reply

Smittysixty Mar. 13 at 5:35 PM

$PPBT The Big Picture Purple Biotech’s latest filing wasn’t “bad news.” It was a strategic reset that tells you exactly where the company is heading: ➡️ Full focus on the CAPTN‑3 tri‑specific antibody platform ➡️ Two development‑ready drugs (IM1240 + IM1305) ➡️ Clean balance sheet ➡️ Runway into 2027 This is a repositioning, not a retreat.

0 · Reply

EJS784 Mar. 13 at 4:42 PM

$PPBT same story every 2-3 years.... 🤦 I hate myself every day for buying into this years ago.

1 · Reply

LetItRip675 Mar. 13 at 4:30 PM

$PPBT I need a cigarette

0 · Reply

Winorbust Mar. 13 at 4:06 PM

$PPBT but everyone hyped Gil, after Isaac. This is a rinse and repeat situation going on. Milk the stock, then swap leaders around, then introduce new drugs

2 · Reply

Winorbust Mar. 13 at 4:04 PM

$PPBT lol earnings but they make $0. Can you tell me what they are currently selling?

2 · Reply

coinspitter Mar. 13 at 3:43 PM

$PPBT CEO leaving in August announcement does not sound like any buyout would be in progress, so short term negative. Lots of shareholder value has been destroyed during his reign, well "he never cared about the shareholders" shouls be written on his stone.

1 · Reply

Purplepayday Mar. 13 at 2:28 PM

$PPBT So i guess that Gill want to be sure that he gets his parachute of 1 year salary before the remaining $9 million disappear….. That’s a very big tell ! Had to resign now, before the bankruptcy.. Yes, i miss Smitty 🥺

1 · Reply

Market Cap	5.27M
Revenue (ttm)	0.00
Net Income (ttm)	-7.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	15,100
Avg Vol	13,419
Day's Range	N/A - N/A
Shares Out	1.29M
Stochastic %K	27%
Beta	0.66
Analysts	Sell
Price Target	$340.00